Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468266 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL4512963 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL31468267 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL31468271 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL5556018 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL23451307 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL31468286 | 1.00 | CA2 (0.39) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL221314 | 0.98 | — | — | |
| SCHEMBL11571033 | 0.94 | EPHX2 (0.37) | CA2EPHX2TSHRALDH1A1NAMPT | |
| SCHEMBL871278 | 0.87 | MEN1 (0.35) | TSHRALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112675716-A | UIO-66-NH2Method for preparing high-flux defect-free polyamide membrane by using derivative | 山东中莱新材料技术有限公司 | 2021-04-20 | — | — | CN | claimed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-118027395-B | Coating material, preparation method and application thereof, and lithium battery diaphragm | 安徽壹石通材料科学研究院有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025064681-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024143485-A1 | COMPOUND, COMPOSITION, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR | 三菱ケミカル株式会社 | 2024-07-04 | — | — | WO | disclosed |
| EP-3678700-B1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | MERCK SHARP & DOHME LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118027395-A | Coating material, preparation method and application thereof, and lithium battery diaphragm | 安徽壹石通材料科学研究院有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230357145-A1 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-11-09 | — | — | US | disclosed |
| CN-112675716-B | UIO-66-NH 2 Method for preparing high-flux defect-free polyamide membrane by using base derivative | 山东中莱新材料技术有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| EP-0344990-B1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KK (JP) | 1993-12-15 | — | — | EP | disclosed |
| US-5254724-A | Method for synthesis of desferrioxamine B, analogs and homologs thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993009088-A1 | IMPROVED METHOD FOR SYNTHESIS OF DESFERRIOXAMINE B, ANALOGS AND HOMOLOGS THEREOF | UNIVERSITY OF FLORIDA (US) | 1993-05-13 | — | — | WO | disclosed |
| US-5021423-A | Antibiotic, antitumor agent | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1991-06-04 | — | — | US | disclosed |
| EP-0344990-A1 | Mitomycin derivatives and intermediates therefor | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0019745-B1 | 2-AMINOPROPANAL ACETALS, THEIR PREPARATION, FUNGICIDAL FORMULATIONS CONTAINING THEM, THEIR PREPARATION AND PROCESS FOR COMBATING FUNGI | BASF Aktiengesellschaft (DE) | 1982-07-28 | — | — | EP | disclosed |
| EP-0019745-A1 | 2-Aminopropanal acetals, their preparation, fungicidal formulations containing them, their preparation and process for combating fungi | BASF Aktiengesellschaft (DE) | 1980-12-10 | — | — | EP | disclosed |
| US-4152526-A | N-acyl derivatives of 3-amino-2,4,6-triiodobenzoic acid | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1979-05-01 | — | — | US | disclosed |
| US-4111937-A | IODINATED ANILIC ACIDS | STERLING DRUG INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4031088-A | Iodinated anilic acids | STERLING DRUG INC. (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357145-A1 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, CNR2 | CA2 1644/4885EPHX2 1011/4885TSHR 1285/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | CA2 690/4885EPHX2 458/4885TSHR 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.